23.12.2014 • NewsExpress ScriptsAbbVieViekira Pak

Express Scripts to Reimburse AbbVie Hepatitis C Drug

The largest pharmacy benefit manager in the US, Express Scripts, has negotiated a cheaper price from AbbVie for its Viekira Pak hepatitis C treatment approved by the US Food and Drug Administration (FDA) on Dec. 19.

The pricing agreement covers Express Scripts' National Preferred Formulary, a list of approved and covered drugs that applies to 25 million Americans with its pharmacy insurance.

In most cases, Express said, it will no longer reimburse a competitive drug made by Gilead Sciences for patients who have the genotype 1 form of the disease - which includes 70% of US patients.

While Gilead's medicines have set a new standard, curing the vast majority of patients in only 12 weeks, the high prices for hepatitis C drugs has opened a national debate in the US about drug prices altogether as well as increasing insurer pressure on drugmakers to cut prices.

Express Scripts has opposed the $84,000 price tag of Gileads' Sovaldi treatment - for the 12-week course of therapy - since it was approved a year ago, on grounds it was unaffordable. Gilead's Harvoni costs $94,500 for 12 weeks of treatment.

AbbVie said the wholesale price of Viekira Pak would be $83,319 for a typical 12-week course. That is less than the Gilead drugs, observers note, but probably not enough of a discount to allay complaints about high prices.

Nonetheless, health plans and pharmacy benefit managers generally negotiate discounts in exchange for a better positioning on the formulary, and AbbVie is believed to be prepared to offer more concessions.

Express Scripts' chief medical officer Steve Miller said the AbbVie offer narrows the gap to the lower prices Western European countries have negotiated for Sovaldi. These are said to range from $51,373 in France to $66,000 in Germany.

According to US reports, pharmacy benefit managers in the recent past have refused to pay at all for their less preferred drug. Express Scripts' national preferred formulary is said to be planning to exclude about 70 drugs in 2015, including Harvoni, Sovaldi and another new hepatitis C drug, Johnson & Johnson's Olysio.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.